Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nanobiotix S.A. - Sponsored ADR (NBTX : NSDQ)

• Company Description    NANOBIOTIX is a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases. NANOBIOTIX is based in CAMBRIDGE, Mass. Number of Employees: 97

• Price / Volume Information    Yesterday's Closing Price: $39.70 Daily Weekly Monthly 20 Day Moving Average: 114,554 shares Shares Outstanding: 50.62 (millions) Market Capitalization: $2,009.61 (millions) Beta: 0.78 52 Week High: $57.14 52 Week Low: $6.09 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 15.31% 14.46% 12 Week 14.67% 11.53% Year To Date 71.71% 58.07%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 RUE DE WATTIGNIES - PARIS,I0 75012 FRA ph: 33-1-40-26-04-70 fax: - None http://www.nanobiotix.com

• General Corporate Information    Officers Laurent Levy - Chairman of the Executive Board and Co-founder Anne-Marie Graffin - Vice Chairwoman Bart Van Rhijn - Chief Financial and Business Officer Alain Herrera - Member Enno Spillner - Member Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 63009J107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 50.62 Most Recent Split Date: (:1) Beta: 0.78 Market Capitalization: $2,009.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - - 03/31/26 - - 12/31/25 - - Current Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - 1.09 Quick Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - 1.09 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - -73.51 Book Value 06/30/26 - - 03/31/26 - - 12/31/25 - -1.97 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©